ROS1 and non-small cell lung carcinoma: We describe a ROS1-fusion positive NSCLC patient with dual F2004V and L2086F resistance mutations overcome by the combination of lorlatinib plus cabozantinib, as evidenced by an impressive radiographic response and undetectable L2086F clone shortly after starting therapy.